Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 153 pages

Showing 101 - 150


solid tumors
sarcoma

Outcomes With Palbociclib at Altered Dose and Schedule in Liposarcoma

In a single-center phase II trial reported in JAMA Oncology, Dickson et al found that changing the dose and schedule of palbociclib (Ibrance) from those in a previous phase II trial appeared to maintain activity while potentially reducing hematologic adverse effects in patients with advanced...

breast cancer
solid tumors

Adding Bevacizumab to Letrozole Improves Progression-Free Survival but Increases Toxicity in Metastatic Breast Cancer

The addition of bevacizumab (Avastin) to first-line endocrine therapy with letrozole improved progression-free survival but increased toxicity among postmenopausal women with hormone receptor–positive metastatic breast cancer, according to the results of the phase III CALGB 40503/Alliance...

solid tumors
hematologic malignancies
issues in oncology
survivorship

Increased Risk of Cardiovascular Disease Among Survivors of Some Adult-Onset Cancers

In a study using managed-care organization data reported in the Journal of Clinical Oncology, Armenian et al found that survivors of adult-onset multiple myeloma, non-Hodgkin lymphoma, lung/bronchus cancer, and breast cancer had an increased risk for subsequent cardiovascular disease. Study...

breast cancer
solid tumors

Neoadjuvant Nab-Paclitaxel Improves Pathologic Complete Response Rate vs Solvent-Based Paclitaxel in Early-Stage Breast Cancer

In the phase III GeparSepto-GBG 69 trial, reported in The Lancet Oncology by Untch et al, neoadjuvant nab-paclitaxel (Abraxane) improved pathologic complete response rate vs conventional solvent-based paclitaxel in women with early-stage breast cancer. Study Details In the open-label trial, 1,206 ...

solid tumors
prostate cancer

Survival Differs With Metastatic Site in Castration-Resistant Prostate Cancer

Overall survival differed according to the site of metastases in men with castration-resistant prostate cancer, according to a meta-analysis reported in the Journal of Clinical Oncology by Halabi et al. Study Details The study involved data from 8,820 men who received docetaxel chemotherapy in...

solid tumors
kidney cancer

Study Finds Apitolisib Less Effective Than Everolimus in Metastatic Renal Cell Carcinoma

As reported in the Journal of Clinical Oncology by Powles et al, the dual PI3K/mTOR inhibitor apitolisib was inferior to the mTOR inhibitor everolimus (Afinitor) in progression-free survival in a phase II trial in patients with metastatic clear cell renal cell carcinoma progressing on or after...

breast cancer
solid tumors

Neratinib Improves Invasive Disease–Free Survival After Trastuzumab-Based Therapy in HER2-Positive Breast Cancer

Chan et al found that 1 year of treatment with the HER1, 2, and 4 tyrosine kinase inhibitor neratinib improved invasive disease–free survival vs placebo after trastuzumab (Herceptin)-based adjuvant therapy in patients with early-stage HER2-positive breast cancer, in the phase III ExteNET...

colorectal cancer
solid tumors

Poorer Outcome With BRAF and KRAS Mutations in Microsatellite-Stable but Not Microsatellite-Unstable Colon Cancer

In an analysis of the PETACC-8 trial reported by Taieb et al in JAMA Oncology, BRAF V600 and KRAS mutations were associated with shorter disease-free and overall survival in patients with microsatellite-stable colon cancer—but not in those with tumors with microsatellite instability—in...

solid tumors

Ga-68 Dotatate PET/CT Improves Detection of Gastroenteropancreatic Neuroendocrine Tumors

In a study reported in the Journal of Clinical Oncology, Sadowski et al found that Ga-68 dotatate positron-emission tomography/computed tomography (PET/CT) improved detection of gastroenteropancreatic neuroendocrine tumors compared with 111In-pentetreotide single-photon emission computed...

solid tumors
solid tumors

High Conditional Survival for Patients With Metastatic Testicular Germ Cell Tumors Receiving First-Line Curative Therapy

Two-year conditional overall and disease-free survival were substantially increased in patients surviving and surviving without recurrence for 2 years after first-line curative therapy for metastatic testicular germ cell tumors, according to a study reported by Ko et al in the Journal of Clinical...

solid tumors
prostate cancer

Increased Survival and Toxicity With Docetaxel, No Apparent Benefit of Zoledronic Acid in Prostate Cancer

As reported in The Lancet by James et al, results of the STAMPEDE trial, which used a multiarm, multistage seamless phase II/III design, showed increased survival and toxicity with docetaxel and little benefit of zoledronic acid when added to first-line long-term hormone therapy in patients with...

lung cancer
solid tumors

French Trial Shows Addition of First-Line Bevacizumab to Cisplatin/Pemetrexed Improves Survival in Malignant Pleural Mesothelioma

In the French phase III MAPS trial reported in The Lancet, Zalcman et al found that the addition of bevacizumab (Avastin) to standard cisplatin/pemetrexed (Alimta) treatment increased overall and progression-free survival in patients with newly diagnosed pleural mesothelioma. Vascular endothelial...

solid tumors
issues in oncology

Increased Risk of Carcinoma of Unknown Primary and Other Cancers in Relatives of Patients With This Type of Cancer

In a study from the Utah Cancer Registry reported in JAMA Oncology, Samadder et al found an increased risk of carcinoma of unknown primary and other cancers in relatives of patients with this type of cancer. Study Details The study was a nested case-control study including 4,160 patients with a...

solid tumors
lung cancer
cns cancers

Everolimus Improves Progression-Free Survival in Advanced Neuroendocrine Tumors of the Lung or Gastrointestinal Tract

In a phase III RADIANT-4 trial reported in The Lancet, Yao et al found that everolimus (Afinitor) and supportive care significantly prolonged progression-free survival vs placebo and supportive care in patients with advanced nonfunctional neuroendocrine tumors of the lung or gastrointestinal tract. ...

solid tumors

Study Reports Improved Survival With Lapatinib and CapeOx in Asian and Younger Patients With HER2-Positive Advanced Gastroesophageal Adenocarcinoma

In a phase III trial (TRIO-013/LOGiC) reported in the Journal of Clinical Oncology, Hecht et al found that the addition of lapatinib (Tykerb) to capecitabine-oxaliplatin (CapeOx) in patients with previously untreated HER2-amplified advanced gastroesophageal adenocarcinoma did not improve overall...

solid tumors

Single-Institution Experience Indicates Improved Outcomes With Higher Radiotherapy Doses in Inoperable Intrahepatic Cholangiocarcinoma

In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Tao et al found that use of higher radiotherapy doses was associated with prolonged local control and overall survival in patients with inoperable intrahepatic cholangiocarcinoma. Overall survival was...

solid tumors

Improved Outcomes With Modified Docetaxel, Cisplatin, and 5-FU vs Standard Regimen Plus Growth Factor Support in Metastatic Gastric Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Shah et al in the U.S. Gastric Cancer Consortium found that a modified regimen of docetaxel, cisplatin, and fluorouracil (5-FU) (mDCF) improved toxicity and survival vs a standard DCF regimen plus growth factor support as first-line...

solid tumors
hepatobiliary cancer

Study Finds No Recurrence-Free Survival Benefit of Adjuvant Sorafenib in Hepatocellular Carcinoma After Resection or Ablation

In the phase III STORM trial reported in The Lancet Oncology, Bruix et al found no benefit with adjuvant sorafenib (Nexavar) treatment in patients who had undergone resection or ablation for hepatocellular carcinoma. Study Details In this double-blind trial, 1,114 patients from 202 sites in 28...

solid tumors
solid tumors

Danish Analysis Indicates Increased Risk of Late Adverse Outcomes in Patients Treated for Relapsed Disseminated Testicular Germ Cell Cancer

In a Danish analysis reported in the Journal of Clinical Oncology, Lauritsen et al found that patients with testicular germ cell cancer who survived after more than one line of treatment for disseminated disease had an increased risk of late toxicity and death resulting from causes other than germ...

solid tumors
gastroesophageal cancer

Long-Term Results of Dutch CROSS Trial Indicate Continued Survival Benefit With Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Initial results of the Dutch phase III CROSS trial showed a significant 5-year overall survival benefit with the addition of neoadjuvant chemoradiotherapy to surgery after a median 45-month follow-up in patients with squamous cell carcinoma or adenocarcinoma of the esophagus or esophagogastric...

solid tumors
solid tumors

Study Finds Increased Short-Term Risk for Cardiovascular Disease Mortality After Chemotherapy for Testicular Nonseminoma

In a population-based study reported in the Journal of Clinical Oncology, Fung et al found a significantly increased risk of cardiovascular disease mortality during the first year after chemotherapy for testicular nonseminoma. No increased risk of cardiovascular disease mortality after surgery was...

solid tumors
pancreatic cancer
prostate cancer
bladder cancer

Analysis Suggests Use of Pioglitazone for Diabetes May Increase Risk of Prostate and Pancreatic Cancers But Not Bladder Cancer

Available data suggest an increased risk of bladder cancer with pioglitazone treatment for diabetes. In an analysis of Kaiser Permanente Northern California data reported in JAMA, Lewis et al found no significantly increased risk of bladder cancer in patients with diabetes ever using pioglitazone....

solid tumors

No Benefit of Adding CT to Basic Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism

In a Canadian study reported in The New England Journal of Medicine, Carrier et al found that adding computed tomography (CT) of the abdomen and pelvis to basic screening did not improve detection of occult cancers in patients with a first episode of unprovoked venous thromboembolism. Venous...

solid tumors

Adjuvant Regimen Produces Good Survival Results in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

In a phase II Intergroup study (SWOG S0809) reported in the Journal of Clinical Oncology, Ben-Josef et al found that adjuvant capecitabine and gemcitabine followed by concurrent radiotherapy and capecitabine produced good survival results in patients with extrahepatic cholangiocarcinoma or...

solid tumors

Nilotinib Inferior to Imatinib in First-Line Treatment of Unresectable or Metastatic GIST

In the phase III ENESTg1 trial reported in The Lancet Oncology, Blay et al found that nilotinib (Tasigna) was associated with poorer progression-free survival vs imatinib (Gleevec) as first-line treatment in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). Trial...

solid tumors

No Survival Benefit of Vorinostat in Progressive Advanced Malignant Pleural Mesothelioma

In the phase III VANTAGE-014 study reported in The Lancet Oncology, Krug et al found that treatment with the histone deacetylase inhibitor vorinostat (Zolinza) did not improve overall survival vs placebo in patients with malignant pleural mesothelioma who had progressed on previous chemotherapy....

solid tumors
issues in oncology

Comprehensive Genomic Profiling Shows Distribution of Targetable Alterations in Carcinomas of Unknown Primary Site

In a study reported in JAMA Oncology, Ross et al found potentially targetable genomic alterations in most carcinomas of unknown primary site using comprehensive genomic profiling. Adenocarcinomas of unknown primary site frequently harbored receptor tyrosine kinase/Ras/MAPK pathway alterations....

gynecologic cancers
solid tumors

Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors

In a study reported in the Journal of Clinical Oncology, Frazier et al used data from U.S. and UK clinical trials to identify a high-risk group of patients with pediatric extracranial germ cell tumors. Study Details The study involved data from seven germ cell tumor trials conducted by the...

solid tumors
bladder cancer

No Overall Survival Difference for Immediate vs Deferred Chemotherapy After Radical Cystectomy in Muscle-Invasive Bladder Cancer

In the phase III EORTC 30994 trial reported in The Lancet Oncology, Sternberg et al found no overall survival difference between immediate and delayed adjuvant chemotherapy after radical cystectomy in patients with muscle-invasive urothelial carcinoma of the bladder. Immediate treatment was...

solid tumors
solid tumors

Intensified Chemotherapy Based on Tumor Marker Decline May Improve Progression-Free Survival in Patients With Poor-Prognosis Germ Cell Tumors

In the phase III GETUG 13 trial reported in The Lancet Oncology, Fizazi et al found that treatment intensification based on early tumor marker decline resulted in a numeric and borderline statistically significant improvement in progression-free survival in patients with poor-prognosis germ cell...

solid tumors
bladder cancer

Novel Genomic Signature Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer

As reported in the Journal of the National Cancer Institute, Mitra et al have identified a novel genomic-based signature that improves prediction of postcystectomy recurrence in patients with high-risk bladder cancer. Use of the signature could help guide selection of patients for adjuvant therapy...

solid tumors
bladder cancer

RTOG Pooled Analysis Shows Good Long-Term Outcomes After Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer

In a pooled analysis of prospective Radiation Therapy Oncology Group (RTOG) studies reported in the Journal of Clinical Oncology, Mak et al found good long-term outcomes with bladder-preserving combined-modality therapy for muscle-invasive bladder cancer. Study Details The analysis included 468...

solid tumors

Good Long-Term Outcomes With Surveillance for Stage I Nonseminoma Testicular Cancer

In a Danish population-based cohort study reported in Journal of Clinical Oncology, Daugaard and colleagues found that surveillance for stage I nonseminoma testicular cancer after orchiectomy was associated with high cure rate and low treatment burden over long-term follow-up. Study Details The...

solid tumors

First-Line FOLFIRI Improves Time to Treatment Failure and Is Better Tolerated vs ECX in Advanced Gastric Cancer

In a phase III French Intergroup trial reported in the Journal of Clinical Oncology, Guimbaud et al found that FOLFIRI (fluorouracil [5-FU], leucovorin, and irinotecan) significantly prolonged time to treatment failure compared with ECX (epirubicin, cisplatin, and capecitabine) in first-line...

solid tumors
solid tumors

Active Surveillance for Clinical Stage I Testicular Cancer Associated With ‘Excellent’ Outcomes

In a retrospective study reported in the Journal of Clinical Oncology, Kollmannsberger et al found that active surveillance for patients with clinical stage I testicular cancer is associated with very good outcomes. Most relapses occurred within 2 years of orchiectomy in patients with nonseminoma...

solid tumors
prostate cancer

Study Suggests That Primary Androgen-Deprivation Therapy Does Not Improve Long-Term Survival in Older Patients With Localized Prostate Cancer

Primary androgen-deprivation therapy has been widely used in localized prostate cancer, despite absence of definitive evidence of benefit in early-stage disease. In a large population-based cohort study reported in JAMA Internal Medicine, Lu-Yao et al found that primary androgen-deprivation therapy ...

solid tumors
prostate cancer

Vasectomy Associated With Modestly Increased Risk of High-Grade and Lethal Prostate Cancer

An analysis of data from the Health Professionals Follow-Up Study reported by Siddiqui et al in the Journal of Clinical Oncology indicates that vasectomy is associated with a modestly but significantly increased risk of high-grade and lethal prostate cancer. The study involved data from 49,405...

solid tumors

No Survival Benefit of Video-Assisted Thoracoscopic Partial Pleurectomy vs Talc Pleurodesis in Malignant Pleural Mesothelioma

In light of nonrandomized studies suggesting benefit of video-assisted thoracoscopic partial pleurectomy (VAT-PP) in symptom control and survival, Rintoul et al performed a randomized trial (MesoVATS) of VAT-PP vs talc pleurodesis in malignant pleural mesothelioma. As reported in The Lancet, this...

solid tumors
gastroesophageal cancer

Adding Rilotumumab to First-Line Chemotherapy May Benefit Patients With Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Hepatocyte growth factor (HGF) and its receptor MET have been found to promote the proliferation, migration, and survival of tumor cells and to play a role in gastric cancer. In a phase II study reported in The Lancet Oncology, Iveson et al found evidence of benefit from adding the anti-HGF...

solid tumors

Phase III Trial Indicates That S-1 Monotherapy Should Remain Standard Treatment of Locally Advanced Gastric Cancer in Japan

The oral fluoropyrimidine S-1 is standard treatment for locally advanced gastric cancer in Japan. In a Japanese phase III trial (SAMIT) in locally advanced disease reported in The Lancet Oncology, Tsuburaya et al found that sequential paclitaxel plus tegafur and uracil or S-1 did not improve...

solid tumors

Adding Lapatinib to Paclitaxel Does Not Improve Survival as Second-Line Therapy in Asian Patients With HER2-Positive Advanced Gastric Cancer

Weekly paclitaxel is used as second-line treatment in advanced gastric cancer, including HER2-positive disease, in Asian countries. In the phase III TyTAN trial in Asian patients reported in the Journal of Clinical Oncology, Satoh et al assessed the addition of the anti-HER2 agent lapatinib...

solid tumors
bladder cancer

Accelerated Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim Is Effective, Well-Tolerated Neoadjuvant Therapy for Bladder Cancer

Although neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer, it is not widely used due to concerns over toxicity and delayed cystectomy. In a phase II trial reported in the Journal of Clinical Oncology, Plimack et al evaluated whether a neoadjuvant...

solid tumors
bladder cancer

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim: Safe and Effective in Muscle-Invasive Urothelial Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that a neoadjuvant four-cycle/8-week regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was well tolerated and effective in patients with muscle-invasive urothelial cancer. Study Details ...

head and neck cancer
solid tumors

No Difference in Disease-Free Survival but Less Steroid Dependence With Adrenal-Sparing Surgery vs Adrenalectomy in Pheochromocytoma

Molecular diagnosis and preventive surgery have been successful in preventing medullary thyroid cancer in patients with multiple endocrine neoplasia type 2 syndrome. In a retrospective population-based study reported in The Lancet Oncology, Castinetti et al found no difference in disease-free...

solid tumors
supportive care

Consumptive Hypothyroidism in GIST Associated With Increased D3 Expression

In a report in The New England Journal of Medicine, Maynard et al discuss identification of consumptive hypothyroidism due to overexpression of thyroid hormone–inactivating enzyme type 3 iodothyronine deiodinase (D3) in a patient with gastrointestinal stromal tumor (GIST) and subsequent...

solid tumors
issues in oncology

Tumor Size, Location, and Mitotic Rate, but Not Genotype, Associated With Recurrence-Free Survival in Trial of Adjuvant Imatinib vs Placebo in GIST

The ACOSOG Z9001 (Alliance) study showed that 1 year of adjuvant imatinib (Gleevec) prolonged recurrence-free survival after resection of primary gastrointestinal stromal tumors (GIST). As reported by Corless et al in the Journal of Clinical Oncology, a study evaluating correlation of pathologic...

solid tumors
prostate cancer

High Incidence of Complications Other Than Urinary Incontinence or Erectile Dysfunction After Prostatectomy or Radiotherapy for Prostate Cancer

Studies of complications of surgery or radiotherapy for prostate cancer generally focus on incontinence and erectile dysfunction. In a population-based cohort study reported in The Lancet Oncology, Nam et al assessed the frequency of other complications associated with such treatment and found high ...

solid tumors

One-Fifth of Hospitalizations for Patients With Gastrointestinal Cancer Considered Avoidable

In a study reported in the Journal of Clinical Oncology, Brooks et al found that oncology clinicians considered 19% of hospitalizations for patients with gastrointestinal cancers to be avoidable. Study Details In the study, 201 sequential hospital admissions in 154 patients with gastrointestinal...

solid tumors

Imatinib Rechallenge Slows Disease Progression in Patients With Metastatic or Unresectable GIST After Imatinib and Sunitinib

In the RIGHT trial, reported in The Lancet Oncology, Yoon-Koo Kang, MD, of University of Ulsan College of Medicine in Seoul, and colleagues assessed the effects of imatinib (Gleevec) rechallenge in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) after objective...

solid tumors

Everolimus Does Not Improve Overall Survival in Previously Treated Advanced Gastric Cancer

In a phase III trial (GRANITE-1 study) reported in Journal of Clinical Oncology by Atsushi Ohtsu, MD, PhD, of the National Cancer Center Hospital East in Kashiwa, Japan, and colleagues, everolimus (Afinitor) plus best supportive care did not prolong overall survival compared with placebo plus best...

Advertisement

Advertisement



Advertisement